X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MW005, our topical enzymatic therapy for the treatment of non-melanoma skin cancers received positive initial data from the Company’s U.S. Phase I/II study of MW005 for the treatment of low-risk basal cell carcinoma (BCC).
Lead Product(s): Bromelain
Therapeutic Area: Oncology Product Name: MW005
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx® (bromelain), establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharXR
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $27.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx. EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, is an easy to use product candidate, for topical daily applications.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharXR
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $27.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 03, 2023
Details:
Through the acquisition, Sun Pharma strengthen its anti-inflammatory portfolio by adding Disperzyme (bromelain), Disperzyme-CD and Phlogam from Aksigen Hospital Care.
Lead Product(s): Bromelain,Trypsin,Rutin
Therapeutic Area: Neurology Product Name: Disperzyme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 30, 2023
Details:
NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
NexoBrid (bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
BARDA is providing funds to develop NexoBrid & support NexoBrid’s potential approval to enhance U.S preparedness. NexoBrid, product for non-surgical eschar removal & full-thickness thermal burns, is a bromelain-based product containing a sterile mixture of proteolytic enzymes.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: $211.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 10, 2022
Details:
The phase II investigator-initiated trial is an open-label study, designed to evaluate the safety and efficacy of MW005 in removing non-melanoma skin cancers and pre-cancerous lesions (e.g., actinic keratosis, BCC, and squamous cell carcinoma) in up to 50 patients.
Lead Product(s): Bromelain
Therapeutic Area: Oncology Product Name: MW005
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
NexoBrid (concentrate of proteolytic enzymes enriched in Bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
MediWound has entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group, an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ghassan Aboud Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 14, 2020
Details:
The completion of the CIDS enrollment stage follows the U.S. Food and Drug Administration (FDA)’s recent agreement to allow the NexoBrid expanded access (NEXT) protocol to be expanded to include pediatric as well as adult burn patients.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
The BLA submission includes a comprehensive set of manufacturing data, multiple preclinical and clinical studies including the pivotal U.S. Phase 3 study of NexoBrid in adult patients with deep partial and/or full-thickness thermal burns up to 30% of total body surface area.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The BLA submission includes a comprehensive set of manufacturing data, multiple preclinical and clinical studies including the pivotal U.S. Phase 3 study of NexoBrid in adult patients with deep partial and full-thickness thermal burns.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
MediWound granted GENFA MEDICA SA right to distribute NexoBrid® in France and Switzerland and Specialty Therapeutics the right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: MediWound
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2020
Details:
The agreement is part of MediWound's global commercialization strategy that will expand the medical and commercial potential of NexoBrid to treat skin burns.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MediWound
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
